Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes

To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl‐peptidase‐4 inhibitors [DPP‐4s] or sulfonylureas.

[1]  Christian Hampp,et al.  Pioglitazone and bladder cancer: FDA's assessment , 2017, Pharmacoepidemiology and drug safety.

[2]  O. Abe,et al.  Refractory Haematuria Resulting From Peritoneal Dissemination of Metastatic Gastric Cancer: Radiation Therapy For A Nodule Infiltrating The Urinary Bladder. , 2017, Urology journal.

[3]  T. Gill,et al.  Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013 , 2016, Diabetes Care.

[4]  Rachael Williams,et al.  Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries , 2016, British Medical Journal.

[5]  R. Desai,et al.  Identification of smoking using Medicare data — a validation study of claims‐based algorithms , 2016, Pharmacoepidemiology and drug safety.

[6]  Robert W Platt,et al.  Pioglitazone use and risk of bladder cancer: population based cohort study , 2016, British Medical Journal.

[7]  E Erdmann,et al.  Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[8]  M. Karagas,et al.  Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study , 2016, Diabetes Therapy.

[9]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[10]  Ronac Mamtani,et al.  Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. , 2015, JAMA.

[11]  W. Bilker,et al.  Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer , 2014, Pharmacoepidemiology and drug safety.

[12]  Chun-Yuh Yang,et al.  Pioglitazone use and the risk of bladder cancer , 2014, The Kaohsiung journal of medical sciences.

[13]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[14]  Carlos Vallarino,et al.  Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights , 2013, Clinical Drug Investigation.

[15]  Yukiko Kawasaki,et al.  Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. , 2013, Diabetes research and clinical practice.

[16]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[17]  Samy Suissa,et al.  The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study , 2012, BMJ : British Medical Journal.

[18]  F. Alla,et al.  Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study , 2012, Diabetologia.

[19]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.

[20]  N. Magrini,et al.  Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[21]  J. Avorn,et al.  Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. , 2010, American journal of epidemiology.

[22]  S. Schneeweiss,et al.  Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data , 2007, Cancer Causes & Control.

[23]  Samuel M. Cohen,et al.  Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action , 2006, Toxicologic pathology.

[24]  J. Robins,et al.  Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. , 2006, American journal of epidemiology.

[25]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[26]  S. Cohen.  Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other Species , 2005 .

[27]  Y. Matsuyama,et al.  Marginal Structural Models as a Tool for Standardization , 2003, Epidemiology.

[28]  Nancee V. Niemeyer,et al.  Thiazolidinedione‐Induced Edema , 2002, Pharmacotherapy.

[29]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[30]  K. Rothman.  Induction and latent periods. , 1981, American journal of epidemiology.

[31]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[32]  Scott R. Smith,et al.  Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide , 2013 .

[33]  Thomas M. MacDonald,et al.  Pioglitazone and bladder cancer: a propensity score matched cohort study. , 2013, British journal of clinical pharmacology.

[34]  D. M. Robinson,et al.  Pioglitazone , 2012, Drugs.

[35]  S. Cohen.  Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.